NASDAQ:XGN Exagen - XGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.43 +0.01 (+0.41%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.35▼$2.4650-Day Range$2.23▼$2.8752-Week Range$2.04▼$9.20Volume9,957 shsAverage Volume25,918 shsMarket Capitalization$40.90 millionP/E RatioN/ADividend YieldN/APrice Target$6.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Exagen MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside167.5% Upside$6.50 Price TargetShort InterestHealthy0.10% of Float Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews Sentiment0.36Based on 4 Articles This WeekInsider TradingSelling Shares$15,658 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.87) to ($1.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.74 out of 5 starsMedical Sector66th out of 1,004 stocksMedical Laboratories Industry4th out of 24 stocks 3.4 Analyst's Opinion Consensus RatingExagen has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.50, Exagen has a forecasted upside of 167.5% from its current price of $2.43.Amount of Analyst CoverageExagen has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.10% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently decreased by 54.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.Environmental SustainabilityThe Environmental Impact score for Exagen is -1.29. Previous Next 1.9 News and Social Media Coverage News SentimentExagen has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Exagen this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,658.00 in company stock.Percentage Held by Insiders38.90% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.90% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($1.87) to ($1.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exagen (NASDAQ:XGN) StockExagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.Read More Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address XGN Stock News HeadlinesMarch 29, 2023 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateMarch 25, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Exagen Inc. Issued By William Blair (NASDAQ:XGN)April 1, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...March 24, 2023 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | americanbankingnews.comCantor Fitzgerald Brokers Reduce Earnings Estimates for Exagen Inc. (NASDAQ:XGN)March 24, 2023 | americanbankingnews.comExagen Inc. (NASDAQ:XGN) Forecasted to Post Q1 2023 Earnings of ($0.49) Per ShareMarch 22, 2023 | americanbankingnews.comAnalysts Set Expectations for Exagen Inc.'s Q1 2024 Earnings (NASDAQ:XGN)March 22, 2023 | americanbankingnews.comExagen (NASDAQ:XGN) Given New $5.00 Price Target at BTIG ResearchApril 1, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.March 22, 2023 | finance.yahoo.comExagen Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2023 | finance.yahoo.comExagen Inc. Reports Fourth Quarter and Full Year 2022 ResultsMarch 20, 2023 | markets.businessinsider.comHere's what Wall Street expects from Exagen's earningsMarch 6, 2023 | finance.yahoo.comExagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023February 27, 2023 | finance.yahoo.comExagen Inc. to Participate in Upcoming March ConferencesFebruary 14, 2023 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) insider upped their holding earlier this yearJanuary 30, 2023 | finance.yahoo.comExagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceDecember 18, 2022 | finance.yahoo.comExagen Inc. (XGN) Stock Historical Prices & Data - Yahoo FinanceNovember 14, 2022 | finance.yahoo.comExagen Inc. Reports Third Quarter 2022 ResultsNovember 8, 2022 | finance.yahoo.comExagen Inc. to Participate in Fourth Quarter Investor ConferencesNovember 1, 2022 | finance.yahoo.comExagen to Announce Third Quarter 2022 Financial Results on November 14, 2022October 19, 2022 | marketwatch.comExagen Names Aballi President, CEO as Rocca Steps Down >XGN - MarketWatchOctober 17, 2022 | globenewswire.comExagen Announces Appointment of John Aballi as CEO - GlobeNewswireOctober 17, 2022 | finance.yahoo.comExagen Announces Appointment of John Aballi as CEOOctober 4, 2022 | streetinsider.comExagen Inc (XGN) Appoints Andrew L. Concoff as Chief Innovation Officer - StreetInsider.comOctober 4, 2022 | globenewswire.comExagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer - GlobeNewswireOctober 4, 2022 | finance.yahoo.comExagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation OfficerSeptember 29, 2022 | businesswire.comThe Worldwide Autoimmune Disease Diagnostics Industry is Projected to Reach $7.1 Billion by 2027 at a 8.91% CAGR - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Email Address XGN Company Calendar Last Earnings11/10/2021Today4/01/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XGN CUSIPN/A CIK1274737 Webwww.exagen.com PhoneN/AFaxN/AEmployees219Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+167.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,390,000.00 Net Margins-98.11% Pretax Margin-104.62% Return on Equity-70.16% Return on Assets-40.01% Debt Debt-to-Equity Ratio0.68 Current Ratio7.55 Quick Ratio7.55 Sales & Book Value Annual Sales$45.56 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.93Miscellaneous Outstanding Shares16,830,000Free Float10,281,000Market Cap$40.90 million OptionableNot Optionable Beta1.26 Key ExecutivesMr. Kamal Adawi M.S. (Age 43)MBA, CFO & Corp. Sec. Comp: $609.62kMr. John Aballi (Age 37)CEO, Pres & Director Ryan DouglasInvestors Relations OfficerMr. John Wegener (Age 53)Sr. VP of Sales and Marketing Dr. Andrew L. Concoff FACRM.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory BoardMr. Mark Hazeltine (Age 48)Chief Bus. Officer More ExecutivesKey CompetitorsPsychemedicsNASDAQ:PMDMDxHealthNASDAQ:MDXHCentogeneNASDAQ:CNTGAkuminNASDAQ:AKUGenetronNASDAQ:GTHView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCSold 411,331 shares on 2/15/2023Ownership: 5.252%Morgan StanleySold 8,705 shares on 2/15/2023Ownership: 2.982%Millennium Management LLCSold 12,921 shares on 2/15/2023Ownership: 0.225%Silvercrest Asset Management Group LLCSold 4,493 shares on 2/14/2023Ownership: 3.091%Platinum Investment Management Ltd.Sold 86,941 shares on 2/13/2023Ownership: 1.624%View All Insider TransactionsView All Institutional Transactions XGN Stock - Frequently Asked Questions Should I buy or sell Exagen stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks. What is Exagen's stock price forecast for 2023? 4 equities research analysts have issued twelve-month target prices for Exagen's stock. Their XGN share price forecasts range from $5.00 to $7.00. On average, they predict the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 167.5% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts. How have XGN shares performed in 2023? Exagen's stock was trading at $2.40 at the beginning of 2023. Since then, XGN stock has increased by 1.3% and is now trading at $2.43. View the best growth stocks for 2023 here. Are investors shorting Exagen? Exagen saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 9,700 shares, a decline of 54.9% from the February 28th total of 21,500 shares. Based on an average daily volume of 23,400 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are sold short. View Exagen's Short Interest. When is Exagen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our XGN earnings forecast. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.04. The business earned $12.25 million during the quarter, compared to the consensus estimate of $12.13 million. Exagen had a negative net margin of 98.11% and a negative trailing twelve-month return on equity of 70.16%. During the same quarter in the prior year, the company earned ($0.34) earnings per share. What guidance has Exagen issued on next quarter's earnings? Exagen issued an update on its first quarter 2023 earnings guidance on Tuesday, March, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $9.20 million-$9.70 million, compared to the consensus revenue estimate of $9.33 million. What is Ron Rocca's approval rating as Exagen's CEO? 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees. When did Exagen IPO? (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair acted as the underwriters for the IPO. What is Exagen's stock symbol? Exagen trades on the NASDAQ under the ticker symbol "XGN." How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Exagen's stock price today? One share of XGN stock can currently be purchased for approximately $2.43. How much money does Exagen make? Exagen (NASDAQ:XGN) has a market capitalization of $40.90 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. How many employees does Exagen have? The company employs 219 workers across the globe. How can I contact Exagen? Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via email at ir@exagen.com. This page (NASDAQ:XGN) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.